Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination

Journal of Evaluation in Clinical Practice

Volumn 17, Issue 6, 2011, Pages 1050-1058

  Chen, Meng Kan ^a   Hung, Hui Fang ^a   Duffy, Stephen ^b   Yen, Amy Ming Fang ^a   Chen, Hsiu Hsi ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cervical cancer; cost effectiveness analysis; human papillomavirus virus; vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DNA TEST; FEMALE; GENETIC ANALYSIS; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; COST-BENEFIT ANALYSIS; DNA, VIRAL; FEMALE; HUMANS; MARKOV CHAINS; MASS SCREENING; PAPILLOMAVIRUS VACCINES; TAIWAN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 80755132089     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2010.01453.x     Document Type: Article

References (61)

1. Cuzick, J., Szarewski, A., Cubie, H., et al., (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362 (9399), 1871-1876. (Pubitemid 37518501)
2. Diaz, M., Kim, J. J., Albero, G., de Sanjose, S., Clifford, G., Bosch, F. X., &, Goldie, S. J., (2008) Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. British Journal of Cancer, 99 (2), 230-238.
3. Kim, J. J., Andres-Beck, B., &, Goldie, S. J., (2007) The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer, 97 (9), 1322-1328. (Pubitemid 350035812)
4. Goldie, S. J., Diaz, M., Kim, S.-Y., Levin, C. E., Van Minh, H., &, Kim, J. J., (2008) Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine, 26 (Suppl. 12), M17-M29.
5. Kim, J. J., Kobus, K. E., Diaz, M., O'Shea, M., Van Minh, H., &, Goldie, S. J., (2008) Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine, 26 (32), 4015-4024.
6. Goldie, S. J., Kim, J. J., Kobus, K., Goldhaber-Fiebert, J. D., Salomon, J., O'Shea, M. K. H., Xavier Bosch, F., de Sanjose, S., &, Franco, E. L., (2007) Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine, 25 (33), 6257-6270. (Pubitemid 47088030)
7. Goldie, S. J., O'Shea, M., Campos, N. G., Diaz, M., Sweet, S., &, Kim, S.-Y., (2008) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine, 26 (32), 4080-4093.
8. Goldie, S. J., Kim, J. J., &, Myers, E., (2006) Chapter 19: cost-effectiveness of cervical cancer screening. Vaccine, 24 (Suppl. 3), S3/164-S3/170.
9. Mandelblatt, J. S., Lawrence, W. F., Gaffikin, L., Limpahayom, K. K., Lumbiganon, P., Warakamin, S., King, J., Yi, B., Ringers, P., &, Blumenthal, P. D., (2002) Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. Journal of the National Cancer Institute, 94 (19), 1469-1483. (Pubitemid 35243745)
10. Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G., &, Santas, C., (2009) Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecologic Oncology, 112 (2), 377-383.
11. Goldie, S. J., Gaffikin, L., Goldhaber-Fiebert, J. D., Gordillo-Tobar, A., Levin, C., Mahe, C., &, Wright, T. C., (2005) Cost-effectiveness of cervical-cancer screening in five developing countries. The New England Journal of Medicine, 353 (20), 2158-2168. (Pubitemid 41653107)
12. Kim, J. J., &, Goldie, S. J., (2008) Health and economic implications of HPV vaccination in the United States (see comment). The New England Journal of Medicine, 359 (8), 821-832.
13. Dasbach, E. J., Insinga, R. P., &, Elbasha, E. H., (2008) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG: An International Journal of Obstetrics and Gynaecology, 115 (8), 947-956. (Pubitemid 351841762)
14. Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., &, Franco, E., (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute, 96 (8), 604-615. (Pubitemid 38584984)
15. Kulasingam, S. L., &, Myers, E. R., (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA, 290 (6), 781-789. (Pubitemid 37432955)
16. Sanders, G. D., &, Taira, A. V., (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerging Infectious Diseases, 9 (1), 37-48. (Pubitemid 36110201)
17. Techakehakij, W., &, Feldman, R. D., (2008) Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine, 26 (49), 6258-6265.
18. Usher, C., Tilson, L., Olsen, J., Jepsen, M., Walsh, C., &, Barry, M., (2008) Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine, 26 (44), 5654-5661.
19. Bergeron, C., Largeron, N., McAllister, R., Mathevet, P., &, Remy, V., (2008) Cost-effectiveness analysis of the Introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Technology Assessment in Health Care, 24 (1), 10-19. (Pubitemid 351158538)
20. Muhlberger, N., Sroczynski, G., Esteban, E., Mittendorf, T., Miksad, R. A., &, Siebert, U., (2008) Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. International Journal of Technology Assessment in Health Care, 24 (2), 184-192. (Pubitemid 351519518)
21. van den Akker-van Marle, M. E., van Ballegooijen, M., van Oortmarssen, G. J., Boer, R., &, Habbema, J. D. F., (2002) Cost-effectiveness of cervical cancer screening: comparison of screening policies. Journal of the National Cancer Institute, 94 (3), 193-204. (Pubitemid 34162753)
22. Bidus, M. A., Maxwell, G. L., Kulasingam, S., Rose, G. S., Elkas, J. C., Chernofsky, M., &, Myers, E. R., (2006) Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstetrics & Gynecology, 107 (5), 997-1005.
23. Goldie, S. J., Kim, J. J., &, Wright, T. C., (2004) Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more (see comment). Obstetrics & Gynecology, 103 (4), 619-631. (Pubitemid 40459019)
24. Sherlaw-Johnson, C., &, Philips, Z., (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. British Journal of Cancer, 91 (1), 84-91. (Pubitemid 39013049)
25. Kim, J. J., Wright, T. C., &, Goldie, S. J., (2002) Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA, 287 (18), 2382-2390. (Pubitemid 34493201)
26. Mandelblatt, J. S., Lawrence, W. F., Womack, S. M., Jacobson, D., Yi, B., Hwang, Y. T., Gold, K., Barter, J., &, Shah, K., (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA, 287 (18), 2372-2381. (Pubitemid 34493200)
27. Kim, J. J., Wright, T. C., &, Goldie, S. J., (2005) Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. Journal of the National Cancer Institute, 97 (12), 888-895. (Pubitemid 41417940)
28. Legood, R., Gray, A., Wolstenholme, J., &, Moss, S., (2006) Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ (Clinical Research Ed.), 332 (7533), 79-85.
29. Taiwan Provincial Department of Health (2006) Vital Statistics in Taiwan, Vol. 1. Taipei: Taiwan Provincial Department of Health.
30. Taiwan Provincial Department of Health (2006) Statistics of Causes of Death, Vol. 1. Taipei: Taiwan Provincial Department of Health.
31. Koong, S. L., Yen, A. M., &, Chen, T. H., (2006) Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. Journal of Medical Screening, 13, S44-S47.
32. Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., &, Matchar, D. B., (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Annals of Internal Medicine, 132 (10), 810-819. (Pubitemid 30317797)
33. Lai, C. H., Huang, H. J., Hsueh, S., et al., (2007) Human papillomavirus genotype in cervical cancer: a population-based study. International Journal of Cancer, 120 (9), 1999-2006. (Pubitemid 46418380)
34. Chen, L. S., Huang, N., Tsay, J. H., Wang, P. J., Chou, Y. J., Chou, P., &, Lee, C. H., (2007) Screening for cervical cancer among female physicians and their relatives in Taiwan: a population-based comparative study. Preventive Medicine, 44 (6), 531-535. (Pubitemid 46817641)
35. Solomon, D., Davey, D., Kurman, R., et al., (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 287 (16), 2114-2119. (Pubitemid 34437346)
36. Briggs, A., Claxton, K., &, Sculpher, M., (2006) Decision Modelling for Health Economic Evaluation. New York: Oxford University Press.
37. Cuzick, J., Clavel, C., Petry, K. U., et al., (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, 119 (5), 1095-1101. (Pubitemid 44116919)
38. Paavonen, J., Jenkins, D., Bosch, F. X., et al., (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 369 (9580), 2161-2170. (Pubitemid 46977438)
39. The Future II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England Journal of Medicine, 356 (19), 1915-1927.
40. You, S-L., (1997) Chapter 3: analysis in incidence and mortality of cervical cancer in Taiwan. In Epidemiological Studies of Cervical Neoplasia in Taiwan, pp. 39-71. Taipei: National Taiwan University.
41. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J., &, Burk, R. D., (1998) Natural history of cervicovaginal papillomavirus infection in young women. The New England Journal of Medicine, 338 (7), 423-428. (Pubitemid 28135669)
42. Franco, E. L., Villa, L. L., Sobrinho, J. P., Prado, J. M., Rousseau, M. C., Desy, M., &, Rohan, T. E., (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. The Journal of Infectious Diseases, 180 (5), 1415-1423. (Pubitemid 29506440)
43. Moscicki, A. B., Hills, N., Shiboski, S., et al., (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA, 285 (23), 2995-3002. (Pubitemid 32550118)
44. Woodman, C. B., Collins, S., Winter, H., Bailey, A., Ellis, J., Prior, P., Yates, M., Rollason, T. P., &, Young, L. S., (2001) Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet, 357 (9271), 1831-1836. (Pubitemid 32539115)
45. Thomas, K. K., Hughes, J. P., Kuypers, J. M., Kiviat, N. B., Lee, S. K., Adam, D. E., &, Koutsky, L. A., (2000) Concurrent and sequential acquisition of different genital human papillomavirus types. The Journal of Infectious Diseases, 182 (4), 1097-1102.
46. Clifford, G. M., Gallus, S., Herrero, R., et al., (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366 (9490), 991-998. (Pubitemid 41323035)
47. Schlecht, N. F., Platt, R. W., Duarte-Franco, E., Costa, M. C., Sobrinho, J. P., Prado, J. C., Ferenczy, A., Rohan, T. E., Villa, L. L., &, Franco, E. L., (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. Journal of the National Cancer Institute, 95 (17), 1336-1343. (Pubitemid 37160867)
48. Song, S. H., Lee, J. K., Oh, M. J., Hur, J. Y., Park, Y. K., &, Saw, H. S., (2006) Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix. International Journal of Gynecological Cancer, 16 (4), 1608-1613.
49. Koong, S.-L., (2003) Evaluation of Cervical Cancer Screening Policy in Taiwan. London: London School of Hygiene and Tropical Medicine.
50. Chan, J. K., Monk, B. J., Brewer, C., et al., (2003) HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. British Journal of Cancer, 89 (6), 1062-1066. (Pubitemid 37239212)
51. Ho, C. M., Chien, T. Y., Huang, S. H., Wu, C. J., Shih, B. Y., &, Chang, S. C., (2004) Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecologic Oncology, 93 (2), 458-464.
52. Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., &, Capocaccia, R., (2007) Trends in cervical cancer survival in Europe, 1983-1994: a population-based study. Gynecologic Oncology, 105 (3), 609-619. (Pubitemid 46734180)
53. Schiffman, M., Herrero, R., Hildesheim, A., et al., (2000) HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA, 283 (1), 87-93. (Pubitemid 30038388)
54. Wright, T. C. Jr, Denny, L., Kuhn, L., Pollack, A., &, Lorincz, A., (2000) HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA, 283 (1), 81-86. (Pubitemid 30038387)
55. Hutchinson, M. L., Zahniser, D. J., Sherman, M. E., et al., (1999) Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer, 87 (2), 48-55. (Pubitemid 29204899)
56. Belinson, J., Qiao, Y. L., Pretorius, R., Zhang, W. H., Elson, P., Li, L., Pan, Q. J., Fischer, C., Lorincz, A., &, Zahniser, D., (2001) Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecologic Oncology, 83 (2), 439-444. (Pubitemid 33033096)
57. Ronco, G., Segnan, N., Giorgi-Rossi, P., et al., (2006) Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. Journal of the National Cancer Institute, 98 (11), 765-774. (Pubitemid 43983300)
58. Mayrand, M. H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlee, F., &, Franco, E. L., (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. The New England Journal of Medicine, 357 (16), 1579-1588. (Pubitemid 47598400)
59. Luoto, R., Raitanen, J., Pukkala, E., &, Anttila, A., (2004) Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953-2010. British Journal of Cancer, 90 (9), 1756-1759. (Pubitemid 38725647)
60. Gimbel, H., Settnes, A., &, Tabor, A., (2001) Hysterectomy on benign indication in Denmark 1988-1998. A register based trend analysis. Acta Obstetricia et Gynecologica Scandinavica, 80 (3), 267-272. (Pubitemid 32173565)
61. Kulasingam, S. L., Kim, J. J., Lawrence, W. F., Mandelblatt, J. S., Myers, E. R., Schiffman, M., Solomon, D., &, Goldie, S. J., (2006) Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). Journal of the National Cancer Institute, 98 (2), 92-100. (Pubitemid 43159963)